Ørsted A/S (DOGEF) vs Merck & Co., Inc. (MRK)

Ørsted A/S is a publicly traded company active in electricity, gas, LNG, energy infrastructure, renewable power, or regulated utility services. Its shares give investors exposure to those activities. The company's performance is influenced by revenue growth, margins, competitive position, capital allocation, regulation, currency movements where relevant, and broader economic and market conditions.

Merck & Co., Inc. develops pharmaceutical products across multiple therapeutic areas, including cardiometabolic disorders, oncology, and infectious diseases. In cancer treatment, its immuno-oncology portfolio, led by Keytruda, represents a significant driver of total revenue. The company also maintains a strong vaccines business focused on preventing pediatric illnesses, alongside Gardasil for human papillomavirus. In addition, Merck markets animal health products. Geographically, 47% of the company’s sales come from its U.S. human health segment, which includes pharmaceuticals and vaccines.